As part of a study undertaken to evaluate the role of prophylactic therapy with clindamycin in patients undergoing total hip replacement (1) , the results of which were inconclusive because there were no early or late hip-joint infections in either the treated or control group of patients, we had the opportunity to determine concentrations of clindamycin in human bone.
Patients .ug/g. The mean ratio of bone-serum clindamycin concentration was 0.40 ± 0.30.
There are few reports of determinations of antibiotic concentrations in human bone. Use of a standard method of measuring antibiotic bone levels such as that developed by Norden (5) is essential to provide reproducible data. Holloway et al. (3) , studying lincomycin in the treatment of patients with osteomyelitis caused by Staphylococcus aureus, found an average bone lincomycin level of 3.3 Mg/g and an average bone-serum concentration ratio of approximately 0.16; all patients had good clinical responses to lincomycin. In experimental animals with osteomyelitis due to S. aureus, lincomycin was more effective than cephalothin at the end of week 2 of therapy, though both were equally efficacious at the end of week 4 (5). The mean ratio of bone-serum clindamycin concentration in our patients (0.40) was greater than the reported ratios for oxacillin (0.05 to 0.20) (4) or lincomycin (0.16) (3) . Further studies are needed to evaluate the efficacy of clindamycin in the treatment of osteomyelitis and in the prophylaxis of infection following total hip arthroplasty.
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